Scynexis Inc. reported success in the dose-ranging phase IIb DOVE study evaluating five regimens of oral SCY-078, compared to standard-of-care fluconazole (FLU), to treat vulvovaginal candidiasis (VVC). Not only did SCY-078 achieve efficacy and tolerability at the lowest dose of 600 mg (300 mg twice daily) – the study was not powered to show statistical significance – but the effect was sustained over the evaluation period. Only one of 27 patients in the SCY-078 600-mg dose arm required rescue antifungal therapy compared to seven of 24 patients in the FLU arm.